Company intelligence / Profile preview
Sail Biomedicines
Cambridge, Massachusetts, United Statessail.bio ↗
- Ownership
- Private
- Employees
- ~125
- Development stage
- Preclinical
01
Overview
Sail Biomedicines is developing a next-generation platform for fully programmable RNA medicines. Its lead technology—Endless RNA—enables durable protein expression in vivo. The company’s preclinical pipeline includes programs targeting infectious disease, rare disease, metabolism, and autoimmune indications. No clinical results have been reported as all programs remain at the preclinical stage as of early 2025.
- Therapeutic areas
- ImmunologyMetabolic DisordersRare DiseasesInfectious Diseases
- Modalities
- Circular RNA (Endless RNA™ or eRNA™)mRNAProgrammable nanoparticles
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Flagship Pioneering is a key backer/incubator.Received grants for malaria work but no specific partners named.
Beyond the preview
Go deeper on Sail Biomedicines.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sail Biomedicines.